NEW YORK, Feb. 26 /PRNewswire/ -- QED International Associates, Inc, administrator for the HealthShares(TM) Indexes, a series of 20 underlying indexes for the HealthShares(TM) Exchange-Traded Funds, today announced that effective at the opening of trading on Friday February 29, 2008, UCB SA (Brussels: UCB.BR) will replace Axcan Pharma, Inc. (Nasdaq (GS): AXCA) in the HealthShares(TM) GI/Gender Health Index. Axcan Pharma is being acquired by an affiliate of TPG Capital, a leading private investment firm founded in 1992.
Companies included in the GI/Gender Health Index are engaged in the research, clinical development and/or commercialization of therapeutic agents for the treatment of a wide variety of diseases including, but not limited to, gastrointestinal disorders such as gastroesophageal reflux disease, heartburn, irritable bowel syndrome, Crohn's Disease and ulcerative colitis; genitourinary disorders such as overactive bladder, urge incontinence, stress incontinence and urinary tract infection; and gender health matters including sexual dysfunction (male and female), endometriosis, benign prostatic hyperplasia, prolapsed womb and reproductive health..
About QED International Associates
QED International Associates, based in New York, is a leading financial industry consulting firm specializing in quantitative modeling and the design, development and maintenance of indexes and Exchange Traded Funds. For more information, visit the company's website at http://www.qedinternational.com
|SOURCE QED International Associates|
Copyright©2008 PR Newswire.
All rights reserved